FAQ: Izotropic Corporation's Exclusive U.S. Patent for Computer-Aided Diagnosis with Breast CT

What is the main announcement from Izotropic Corporation?

Izotropic Corporation has secured the exclusive U.S. patent for computer-aided diagnosis (CADx) with breast CT technology, covered under their global license agreement with the Regents of the University of California.

What is computer-aided diagnosis (CADx) and how does it work?

CADx is an AI software tool that analyzes medical images to estimate malignancy likelihood and supports radiologists in interpreting scans by detecting subtle abnormalities and improving diagnostic consistency.

Why is this patent significant for breast cancer detection?

This technology addresses limitations of current breast imaging methods like mammography, digital breast tomosynthesis, ultrasound, and MRI by improving detection capabilities, reducing read times, and streamlining workflows for radiologists.

Who owns the rights to this technology?

Izotropic Corporation holds the exclusive global license for this technology through an agreement with the Regents of the University of California, making them the sole patent holder in the U.S. for CADx with breast CT.

What are the key benefits of this CADx technology?

The technology helps detect subtle abnormalities, improves diagnostic consistency, reduces read times for radiologists, and streamlines workflow processes in breast cancer screening and diagnosis.

Where can I find more information about Izotropic Corporation?

More information can be found on their website at izocorp.com and by reviewing their profile on SEDAR at sedarplus.ca.

How can investors stay updated on Izotropic’s latest news?

Investors can access the latest news and updates relating to IZOZF in the company’s newsroom at https://ibn.fm/IZOZF.

What is the full context of this announcement?

To view the full press release with complete details, visit https://ibn.fm/hSZTc for comprehensive information about the patent and its implications.